ChemRegen

Name

ChemRegen

Legal name

ChemRegen, Inc.

Website

https://chemregen.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Regenerative medicine drugs
• Small molecule therapeutics
• Stem cell differentiation
• Cardiac regeneration therapy
• Cancer stem cell inhibitors

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Regenerative Medicine Research Services: ChemRegen provides its expertise to scientists in the pharmaceutical, biotech and academic communities to develop regenerative medicines. The company intends to expand this business significantly in the coming years.
2. Drug Development and Licensing: Development of proprietary small molecule regenerative medicine candidates for partnership with pharmaceutical companies. Revenue from licensing deals, milestone payments, and royalty arrangements upon successful clinical development.
3. Research Grants and Non-Dilutive Funding: Funding from organizations such as the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute, and California Institute for Regenerative Medicine (CIRM) to support research programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ChemRegen is a regenerative medicine R&D company that develops proprietary small molecule drug candidates combining stem cell biology with medicinal chemistry for cardiac regeneration and cancer treatment. The company conducts preclinical drug development from bench to clinic, prepares for IND filings, and intends to license its compounds to pharmaceutical partners. Its pipeline includes ITD-1 for heart regeneration, PAWI-2 for pancreatic cancer, RIN1 for hematologic cancers, plus lead compounds for breast and colorectal cancer.

Product overview

ChemRegen is a regenerative medicine research and development company developing small molecule drugs for heart disease and cancer. The company's portfolio includes ITD-1 (cardiac regeneration via stem cell differentiation), PAWI-2 (pancreatic cancer treatment), RIN1 (hematologic cancer treatment), and lead compounds for breast and colorectal cancers. The cardiac regeneration platform represents a first-in-class approach using small molecules to stimulate endogenous stem cells to regenerate heart tissue, offered as a pill or injection rather than surgery or transplant.

Differentiator

Problem solved

Functional benefit

Products and services

• ITD-1 Small molecule regenerative medicine compound that is the first selective inhibitor of TGFβ signaling. ITD-1 triggers degradation of the TGFβ receptor, causing stem cells to differentiate into cardiomyocytes. It is being developed to treat heart disease by limiting scar spreading in heart failure and promoting new muscle formation.
• PAWI-2

Quantifiable outcome

• ITD-1 is the first selective inhibitor of TGFβ, enabling stem cell differentiation into cardiomyocytes
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered minor and core.

• FuzeBoxminorOthers · 26 September 2012FuzeBox CEO Jeff Cavins appointed to ChemRegen Board of Directors to help understand future potential of telemedicine as it relates to stem cell therapy research. FuzeBox provides visual collaboration technology for healthcare and biotech organizations.
• Human BioMolecular Research Institute (HBRI)coreStrategic or Co-development Partner · 1 January 2009Long-standing collaboration with HBRI founded by Dr. John Cashman. HBRI provides medicinal chemistry expertise and conducts basic research in drug discovery. Key collaborators include John Cashman who serves as both HBRI President and ChemRegen COO. Jointly developed compounds including ITD-1, PAWI-2, and RIN1.
• Sanford-Burnham Medical Research InstitutecoreStrategic or Co-development Partner · 1 January 2009Initial technology based on collaboration with Dr. Mark Mercola of Sanford-Burnham, a recognized authority on stem cell biology. Sanford-Burnham provides world-class capabilities in stem cell research and drug discovery. Joint research led to discovery of ITD-1 for cardiac regeneration.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Capricor Therapeutics: San Diego-based clinical-stage biotech developing cell-derived exosome and cell therapy candidates for Duchenne muscular dystrophy and cardiac indications. Direct peer because it is a San Diego regenerative-medicine biotech pursuing cardiac disease with novel biology-derived therapeutics.
• Tenaya Therapeutics: Clinical-stage biotech developing gene therapies and small molecules for heart failure and cardiac regeneration. Direct peer because it is focused on regenerating lost cardiomyocytes through novel modalities in the same cardiac indication space as ChemRegen's ITD-1.
• BioCardia: Clinical-stage company developing cell-based therapies for cardiac conditions with a proprietary delivery platform. Direct peer because it targets heart failure regeneration with a different modality but in the same indication, creating licensing-style partnership dynamics similar to ChemRegen's model.
• Vericel Corporation: Commercial-stage cell therapy company with cardiac and orthopedic programs including cardiac repair indications. Direct peer as a company monetizing cell-based and regenerative approaches to heart disease through licensing and commercial sales.
• Caladrius Biosciences: Clinical-stage company developing cell-based therapies for cardiac and autoimmune indications including CD34+ cell therapy for ischemic heart disease. Direct peer because it is a small-cap regenerative medicine biotech pursuing cardiac indications through licensing and partnership deals analogous to ChemRegen's intended model.
• Athersys: Clinical-stage regenerative medicine company developing stem cell therapies for inflammatory, cardiovascular, and neurological indications. Direct peer because it pursues multi-program stem cell and regenerative medicine development with a similar partnership-driven commercialization model.

Emerging players

• OncoMed Pharmaceuticals: Historically focused on targeting cancer stem cells across multiple solid tumors with biologics and small molecules, with programs in pancreatic, breast, and colorectal cancers. Emerging-player peer because it pursued the same cancer stem cell hypothesis in the same indications as ChemRegen's PAWI-2 and related oncology assets.

Regional players

• Heartseed: Japan-based clinical-stage biotech developing iPSC-derived cardiomyocyte cell therapy for heart failure. Regional peer because it competes in the cardiac regeneration indication space with a different modality but the same disease target, illustrating alternative paths ChemRegen's ITD-1 could be benchmarked against.

Broad incumbents

• Boston Biomedical (Daiichi Sankyo): Oncology subsidiary of Daiichi Sankyo developing small molecules targeting cancer stem cell pathways including in pancreatic and colorectal cancers. Broad incumbent because it operates in the same cancer stem cell targeting space with much greater resources and a similar partnership/licensing trajectory.
• Cytokinetics: Late-stage biopharma developing small-molecule cardiac myosin modulators for heart failure and HCM. Broad incumbent because it operates a small-molecule cardiac drug platform with substantially greater resources, providing a competitive benchmark for any eventual ChemRegen cardiac asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemRegen